2. Sarepta Therapeutics announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. Press release. Sarepta Therapeutics. October 30, 2023. Accessed February 5, 2024. https://investorrelations.sarepta.com/news-releases/news-releasedetails/sarepta-therapeutics-announces-topline-results-embark-global-0 3. National Institutes of Health. Duchenne muscular dystrophy. Accessed January 16, 2024. https://rarediseases.info.nih.gov/diseases/6291/duchennemuscular-dystrophy 4.